These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31848044)

  • 21. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
    McNamara JJ; McColley SA; Marigowda G; Liu F; Tian S; Owen CA; Stiles D; Li C; Waltz D; Wang LT; Sawicki GS
    Lancet Respir Med; 2019 Apr; 7(4):325-335. PubMed ID: 30686767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
    Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
    Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
    Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of lumacaftor/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression: Interim results from an ongoing registry-based study.
    Kim C; Higgins M; Liu L; Volkova N; Zolin A; Naehrlich L;
    J Cyst Fibros; 2024 May; 23(3):436-442. PubMed ID: 38402082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical, economic, and societal burden of cystic fibrosis and the impact of the CFTR modulator, lumacaftor/ivacaftor: an assessment using linked registry data in Sweden.
    Lindblad A; Monestrol I; Gilljam M; Krantz C; McGarry LJ; Banefelt J; Aldvén M
    J Med Econ; 2024; 27(1):897-906. PubMed ID: 38939921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor.
    Rubin JL; O'Callaghan L; Pelligra C; Konstan MW; Ward A; Ishak JK; Chandler C; Liou TG
    Ther Adv Respir Dis; 2019; 13():1753466618820186. PubMed ID: 30803355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease.
    Hubert D; Chiron R; Camara B; Grenet D; Prévotat A; Bassinet L; Dominique S; Rault G; Macey J; Honoré I; Kanaan R; Leroy S; Desmazes Dufeu N; Burgel PR
    J Cyst Fibros; 2017 May; 16(3):388-391. PubMed ID: 28325531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.
    Talamo Guevara M; McColley SA
    Expert Opin Drug Saf; 2017 Nov; 16(11):1305-1311. PubMed ID: 28846049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-life experience with a generic formulation of lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for the Phe508del CFTR mutation.
    Teper A; Lubovich S; Rodríguez V; Zaragoza S; Rodríguez E; Bournissen FG
    Pediatr Pulmonol; 2023 Dec; 58(12):3560-3565. PubMed ID: 37712606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment.
    Ejiofor LCK; Mathiesen IHM; Jensen-Fangel S; Olesen HV; Skov M; Philipsen LKD; Pedersen CL; Pressler T
    Pediatr Pulmonol; 2020 Dec; 55(12):3364-3370. PubMed ID: 32897653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-life acute lung function changes after lumacaftor/ivacaftor first administration in pediatric patients with cystic fibrosis.
    Labaste A; Ohlmann C; Mainguy C; Jubin V; Perceval M; Coutier L; Reix P
    J Cyst Fibros; 2017 Nov; 16(6):709-712. PubMed ID: 28529073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction.
    Wark PAB; Cookson K; Thiruchelvam T; Brannan J; Dorahy DJ
    BMC Pulm Med; 2019 Jun; 19(1):106. PubMed ID: 31208380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function.
    Burgel PR; Durieu I; Chiron R; Mely L; Prevotat A; Murris-Espin M; Porzio M; Abely M; Reix P; Marguet C; Macey J; Sermet-Gaudelus I; Corvol H; Bui S; Biouhee T; Hubert D; Munck A; Lemonnier L; Dehillotte C; Silva JD; Paillasseur JL; Martin C;
    J Cyst Fibros; 2021 Mar; 20(2):220-227. PubMed ID: 32591294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive factors for lumacaftor/ivacaftor clinical response.
    Masson A; Schneider-Futschik EK; Baatallah N; Nguyen-Khoa T; Girodon E; Hatton A; Flament T; Le Bourgeois M; Chedevergne F; Bailly C; Kyrilli S; Achimastos D; Hinzpeter A; Edelman A; Sermet-Gaudelus I
    J Cyst Fibros; 2019 May; 18(3):368-374. PubMed ID: 30595473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR.
    Taylor-Cousar JL; Jain M; Barto TL; Haddad T; Atkinson J; Tian S; Tang R; Marigowda G; Waltz D; Pilewski J;
    J Cyst Fibros; 2018 Mar; 17(2):228-235. PubMed ID: 29126871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6-11 with cystic fibrosis in a real-world setting.
    McNally P; Linnane B; Williamson M; Elnazir B; Short C; Saunders C; Kirwan L; David R; Kemner-Van de Corput MPC; Tiddens HAWM; Davies JC; Cox DW
    Respir Res; 2023 Aug; 24(1):199. PubMed ID: 37568199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV
    McColley SA; Konstan MW; Ramsey BW; Stuart Elborn J; Boyle MP; Wainwright CE; Waltz D; Vera-Llonch M; Marigowda G; Jiang JG; Rubin JL
    J Cyst Fibros; 2019 Jan; 18(1):94-101. PubMed ID: 30146268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.
    Davies JC; Sermet-Gaudelus I; Naehrlich L; Harris RS; Campbell D; Ahluwalia N; Short C; Haseltine E; Panorchan P; Saunders C; Owen CA; Wainwright CE;
    J Cyst Fibros; 2021 Jan; 20(1):68-77. PubMed ID: 32967799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.